Explore the options in indolent non-Hodgkin lymphoma (iNHL) with downloadable slides from our iNHL meeting series. Stay informed on the treatment and management of iNHL in high-risk patients, those with comorbid conditions, and patients with potential contraindicated drugs.
Feb 14, 2018
Feb 14, 2019
Managing the Challenging Patient: A Focus on Patients with iNHL
Jonathon B. Cohen, MD, MS
This activity has been designed to meet the needs of medical oncologists and hematologists, nurses, physician assistants, nurse practitioners, and other healthcare professionals who treat or manage patients with iNHL.
After successful completion of this educational activity, participants should be able to:
- Select optimal therapy based on patient and disease characteristics
- Identify proper sequence of therapeutic options for specific patients
- Compare side effect profiles of targeted therapies and select the most appropriate treatment based on patient and disease characteristics
This educational activity is supported by a grant from Gilead Sciences, Inc.
Enduring Materials From a Certified Activity
This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.
This activity is provided by prIME Oncology.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.